In a phase II single-arm study published in 2016, the use of lactobacillus brevis CD2 reduced the incidence of oral mucositis in patients with hematological disorders undergoing high-dose chemotherapy plus HSCT; despite the immunosuppressed status of these patients, no positive blood cultures for lactobacillus brevis CD2 were identified [52]. The gene discussed is CD2; the disease is hematologic disorder.